Active, not recruitingPhase 2NCT04273139
Ibrutinib + Venetoclax in Untreated WM
Studying Waldenström macroglobulinemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dana-Farber Cancer Institute
- Principal Investigator
- Jorge J Castillo, MDDana-Farber Cancer Institute
- Intervention
- IBRUTINIB(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2028
Study locations (2)
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
Collaborators
AbbVie · Pharmacyclics LLC.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04273139 on ClinicalTrials.govOther trials for Waldenström macroglobulinemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07387471Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)AbbVie
- RECRUITINGPHASE2NCT05099471Efficacy of Venetoclax in Combination With Rituximab in Waldenström's MacroglobulinemiaChristian Buske
- RECRUITINGPHASE2NCT06561347Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WMMassachusetts General Hospital
- RECRUITINGPHASE2NCT05190705Loncastuximab Tesirine in WMShayna Sarosiek, MD
- RECRUITINGNCT05093153Spanish Registry of Patients With IgM Monoclonal GammopathiesFundación Española de Hematología y Hemoterapía
- ACTIVE NOT RECRUITINGPHASE2NCT04624906Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's MacroglobulinemiaSunnybrook Health Sciences Centre
- RECRUITINGPHASE2, PHASE3NCT04061512Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's MacroglobulinaemiaUniversity College, London
- ACTIVE NOT RECRUITINGPHASE1NCT01209871Vaccine Therapy in Treating Patients With Lymphoplasmacytic LymphomaM.D. Anderson Cancer Center